Q2 Earnings Estimate for Pharvaris Issued By Leerink Partnrs

Pharvaris (NASDAQ:PHVS) – Research analysts at Leerink Partnrs lifted their Q2 2025 earnings estimates for Pharvaris in a report issued on Tuesday, May 13th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.87) for the quarter, up from their prior forecast of ($0.91). The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Pharvaris’ Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.88) EPS, FY2025 earnings at ($3.58) EPS and FY2026 earnings at ($3.26) EPS.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.09).

Several other research firms have also weighed in on PHVS. Cantor Fitzgerald lowered their target price on shares of Pharvaris from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday. JMP Securities upped their price objective on shares of Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, January 31st.

Pharvaris Price Performance

Pharvaris stock opened at $15.91 on Friday. The firm has a market capitalization of $831.93 million, a P/E ratio of -5.68 and a beta of -2.85. The stock has a fifty day moving average price of $15.37 and a two-hundred day moving average price of $17.73. Pharvaris has a 52-week low of $11.51 and a 52-week high of $25.50.

Institutional Trading of Pharvaris

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its position in Pharvaris by 1,125.3% during the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock worth $59,000 after buying an additional 2,847 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Pharvaris in the fourth quarter worth about $64,000. Barclays PLC acquired a new position in shares of Pharvaris during the third quarter worth approximately $106,000. KLP Kapitalforvaltning AS bought a new stake in shares of Pharvaris during the fourth quarter valued at approximately $111,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Pharvaris during the fourth quarter valued at approximately $152,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.